Ori Biotech

Introducing IRO®, the new standard in CGT manufacturing technology. 🎉 Manufacturing remains a critical barrier to scaling cell and gene therapies – making it difficult to meet the patient need, and limiting the clinical and commercial impact of this new class of therapies. That’s why we developed IRO®. IRO® combines an efficient and flexible platform with a scalable, digital solution to industrialize precision medicine manufacturing – delivering a seamless transition from R&D into the clinic, and from clinical scale to commercial scale. By empowering scientists with tools that help accelerate product development and Automate Better Biology, we are working to help enable widespread patient access and scale the impact of life-changing cell and gene therapies. Thank you to everyone who attended our launch at ISCT today. It's an incredibly exciting moment to finally unveil our work over the past 5-years – we are very grateful to the Ori team and our partners for helping us achieve this milestone. Read our full press release: https://lnkd.in/eT3B3MSf Schedule a hands on demo to see how IRO® could work for you: https://lnkd.in/eXEXEGZZ #ISCT2024 #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #Biotechnology

✨ As the year draws to a close, we're reflecting on the transformative patient stories from 2024 2024 has been a pivotal year for the cell and gene therapy industry, and patient stories have demonstrated the incredible potential of these therapies – and the work still ahead to make them accessible to all. From Sophie Mulligan’s new lease on life with CAR-T therapy to Jimi Olaghere’s journey with CRISPR technology, stories like these drive the work we do every day, ensuring that life-changing therapies are not just approvable but accessible and affordable to those who need them most. Here's a selection of inspiring patient journeys from the year: 1️⃣ https://lnkd.in/ep3AP92b 2️⃣ https://lnkd.in/eyvAbwgA  3️⃣ https://lnkd.in/ef8wxdiu 4️⃣ https://lnkd.in/eEZvvmj6 5️⃣ https://lnkd.in/efDaCRRK #CellTherapy #GeneTherapy #Biotechnology #ManufacturingBrighterFutures #PatientAccess 

🦾 This year, the conversation has grown louder around the need for scalability and flexibility in CGT manufacturing to ensure the commercial viability of these therapies. As we work towards our mission of enabling widespread patient access, we're proud to have contributed to this conversation alongside industry leaders – highlighting what’s possible when innovation meets collaboration. Here's how we've contributed to the conversation this year and are helping to scale the impact of CGTs: 1️⃣ IRO® launch: https://lnkd.in/epRnmgnE  2️⃣ Collaboration with Charles River Laboratories: https://lnkd.in/gjj3P3GG  3️⃣ Collaboration with CTMC: https://lnkd.in/ecnJmryM  4️⃣ Frontrunners in automated CGT manufacturing: https://lnkd.in/dx9j3gg4  5️⃣ Exploring CGT’s future in Cell & Gene features part 1&2: https://lnkd.in/eGuMr4J3 #IRO #TheNewStandard #AccelerateProductDevelopment #ScaleYourImpact #AutomateBetterBiology

🧬 Advancing therapies, overcoming barriers, and expanding patient access... 2024 has been a year of breakthroughs in cell and gene therapy, from the first CAR-T trials for pediatric lupus patients to CRISPR-based approvals for sickle cell disease. While these achievements mark significant progress, they also underscore the urgent need to address manufacturing challenges to ensure these therapies can reach their full potential. Looking to 2025, the focus must remain on ensuring they are not only approvable but accessible and affordable too. Here are six standout stories from 2024 that highlight the strides made ⬇️ 1️⃣ https://lnkd.in/ejQsRJif 2️⃣ https://lnkd.in/dBRART72 3️⃣ https://lnkd.in/gTFfZZh8 4️⃣ https://lnkd.in/dNEhYt4t 5️⃣ https://lnkd.in/gcpEbyPF 6️⃣ Bloomberg: https://lnkd.in/eGsridUQ STAT: https://lnkd.in/g8t-3Bsv #CellTherapy #GeneTherapy #Biotechnology #ManufacturingBrighterFutures #PatientAccess

🧬 As we work towards enabling widespread patient access to cell and gene therapies, we must keep the impact on patients and their families at the front of our minds. It's wonderful to see Great Ormond Street Hospital Charity spotlighting patients and their families who have undergone CAR-T cell therapy, as they share their experiences and offer advice to others navigating their journey ⬇️ #PatientAccess #CellTherapy #GeneTherapy #Biotechnology https://lnkd.in/eUk-h36C

Our CEO Jason C. Foster will be speaking at the William Blair Innovator Series Event tomorrow. 📆 Tuesday, December 17 ⏰ 10:00am ET 📍 Online William Blair’s Innovator Series, an exclusive event for their clientele, is a dynamic virtual event which offers investors the chance to discover some of the most exciting private companies in the industry. Jason will share how IRO® addresses today's CGT manufacturing bottlenecks to help expand patient access and scale clinical and commercial impact of life-saving therapies. #IRO #TheNewStandard #AccelerateProductDevelopment #ScaleYourImpact #AutomateBetterBiology

🔬 Immunotherapy promised to defeat cancer – what’s holding it back? From the groundbreaking approval of CAR-T therapies to the potential of immune checkpoint inhibitors, immunotherapy has changed cancer treatment. Yet, significant barriers like high costs, limited scalability and challenges tackling solid tumors have hindered progress. New approaches to immunotherapy, such as gamma-delta CAR-T-cell therapies – that act as delivery vehicles for anti-cancer antibodies – could help address these challenges. Initial studies suggest that this approach could help lower costs, cut vein-to-vein times, and significantly expand patient access. By rethinking how we manufacture and deliver therapies, we can make these treatments more accessible and affordable – transforming patient care and ensuring we meet the growing demand for life-changing solutions. Read more: https://lnkd.in/eTvjUrHw #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

🔬 Rethinking manufacturing and embracing decentralization can bring therapies closer to patients. In the second of a five-part series – co-authored by Jason C. Foster, Molly Borchardt at Precision AQ, Philip Cyr at Precision AQ, and Erin Lopata at Precision AQ – published on CGTLive, the focus turns to how decentralized manufacturing could transform access to cell and gene therapies. Centralized production has long been the default for CGT manufacturing, but it’s proving inadequate for personalized, time-sensitive treatments. Patients face extended vein-to-vein times, logistical hurdles and high costs that limit access to these life-saving therapies. Decentralized manufacturing offers an alternative. Shifting production closer to treatment centers could reduce delays, cut transportation costs, and accelerate access to critical treatments. Read the second part in the CGTLive series exploring how manufacturing innovation can break down barriers to patient access ⬇️ https://lnkd.in/ekPN4Yyg #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

🔬Are two CARs better than one? The Gates Institute has launched a Phase I trial for a new CAR-T therapy targeting pediatric and young adult patients with relapsed or refractory pre-B-cell acute lymphoblastic leukemia (B-ALL). This new therapy packages two CARs in one treatment, targeting both CD19 and CD22 markers to address the challenge of antigen loss – a common cause of relapse in CAR-T patients. Manufactured at the Gates Biomanufacturing Facility, this dual-antigen approach could increase precision and potentially improve the durability of CAR-T therapy. As the momentum of CAR-T therapy approvals increases, refining each step – from early product development to scaling manufacturing processes – is crucial to drive the industry closer to realizing the full potential of these incredible therapies. Read more: https://lnkd.in/gur5kAF8 #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

We're collaborating with Fresenius Kabi to enhance efficiency in CGT manufacturing 🎉 Together, we've successfully integrated our IRO® platform with Fresenius Kabi's upstream and downstream processing technologies – Cue® and Lovo® Cell Processing Systems – to deliver an efficient and closed workflow. The successful integration of these leading technology platforms demonstrates a streamlined, closed workflow for cell therapy manufacturing that reduces process steps, tube and bag-based transfers and operator touch time. By developing applications and closed integrations with other best-in-class technologies, like Cue and Lovo, IRO offers manufacturers a significant step toward achieving a closed, end-to-end workflow that provides optimal flexibility and scalability while maintaining product quality and consistency. “Our goal is to partner with leading technology providers that offer proven solutions for the unit operations most critical to the success, consistency, and delivery of GMP manufacturing of cell therapies. By doing the application development work to integrate the IRO with other best-in-class systems, like Cue and Lovo, we are demonstrating our commitment to delivering flexible solutions that meet the evolving needs of cell therapy manufacturing, in contrast to rigid end-to-end approaches that reduce flexibility.” Jason C. Foster, Ori CEO Read the announcement ➡️ https://lnkd.in/en7TDjnc #IRO #TheNewStandard #AutomateBetterBiology #ScaleYourImpact